Large‐scale pathogenicity prediction analysis of cancer‐associated kinase mutations reveals variability in sensitivity and specificity of computational methods
Cancer Medicine · 2023
DOI: 10.1002/cam4.6324 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Sravani Akula und 8 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Medicine and Therapeutics Laboratory, CPMB, Osmania University, Hyderabad, India. Hauptthemen laut MEDLINE: Software, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Background
Mutations in kinases are the most frequent genetic alterations in cancer; however, experimental evidence establishing their cancerous nature is available only for a small fraction of these mutants.
Aims
Predicition analysis of kinome mutations is the primary aim of this study. Further objective is to compare the performance of various softwares in pathogenicity prediction of kinase mutations. Materials and methods We employed a set of computational tools to predict the pathogenicity of over forty‐two thousand mutations and deposited the kinase‐wise data in Mendeley database (Estimated Pathogenicity of Kinase Mutants [EPKiMu]).
Results
Mutations are more likely to be drivers when being present in the kinase domain (vs. non‐kinase domain) and belonging to hotspot residues (vs. non‐hotspot residues). We identified that, while predictive tools have low specificity in general, PolyPhen‐2 had the best accuracy. Further efforts to combine all four tools by consensus, voting, or other simple methods did not significantly improve accuracy.
Discussion
The study provides a large dataset of kinase mutations along with their predicted pathogenicity that can be used as a training set for future studies. Furthermore, a comparative sensitivity and selectivity of commonly used computational tools is presented.
Conclusion
Primary‐structure‐based in silico tools identified more cancerous/deleterious mutations in the kinase domains and at the hot spot residues while having higher sensitivity than specificity in detecting deleterious mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Medicine and Therapeutics Laboratory, CPMB, Osmania University, Hyderabad, India.
- Thoracic Oncology, Inova Schar Cancer Institute, Fairfax, Virginia, USA.
- Applied Computational Intelligence Lab, Missouri University of Science and Technology, Rolla, Missouri, USA.
ORCID-Profile: Rama Krishna Kancha
Förderung
- Indian Council of Medical Research
Zitieren
APA
Akula, S., Mullaguri, S. C., Melton, N. M., Katta, A., Naga, V. S. G. R., Kandula, S., Pedada, R. K., Subramanian, J., & Kancha, R. K. (2023). Large‐scale pathogenicity prediction analysis of cancer‐associated kinase mutations reveals variability in sensitivity and specificity of computational methods. Cancer Medicine. https://doi.org/10.1002/cam4.6324
Vancouver
Akula S, Mullaguri SC, Melton NM, Katta A, Naga VSGR, Kandula S, et al. Large‐scale pathogenicity prediction analysis of cancer‐associated kinase mutations reveals variability in sensitivity and specificity of computational methods. Cancer Medicine. 2023. doi:10.1002/cam4.6324
BibTeX
@article{Akula2023,
author = {Akula, Sravani and Mullaguri, Sai Charitha and Melton, Niklas Max and Katta, Archana and Naga, Venkata Sai Giridhar Reddy and Kandula, Shyamson and Pedada, Raj Kumar and Subramanian, Janakiraman and Kancha, Rama Krishna},
title = {Large‐scale pathogenicity prediction analysis of cancer‐associated kinase mutations reveals variability in sensitivity and specificity of computational methods},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6324}
}
EUVIMED